Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76				Attorne	y Docl	ket N	umber	RBL0	RBL0109-01			
				1.70	Applica	ation N	umbe	r				
Title of Invention GALACTOMANNANS AND/OR GLUCOMANNANS FOR INCREASING THE BIOAVAILABILITY OF ACT SUBSTANCES								CTIVE				
The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76. This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.												
Secrecy Order 37 CFR 5.2												
Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)												
Applic	cant Info	rmati	on:									
Applic	ant 1											
	ant Authorit	y lnv	entor 🔘	Legal R	epresentativ	e unde	r 35 l	35 U.S.C. 117 Party of Interest		Party of Interest under 35 U.S.	t under 35 U.S.C. 118	
Prefix				1	Middle Name				Family Name		Suffix	
	Andreas								Hefel			
Resid	ence Inform	ation (S	Select One) () U	JS Residenc	у (•) No	n US Res	sidency	Active US Military Service		
City	Berlingen			Cou	ntry Of Re	esiden	cei	СН				
Citizer	ship under	37 CFR	1.41(b) i	СН		<u> </u>						
Mailing	g Address of	f Applic	cant:									
Addres	ss 1	W	/ieslistrasse	36						•		
Addres	ss 2											
City	Berlinge	n					Stat	e/Provin	ice			
Postal	Code	С	H-8267			Cour	ntryi	СН				
	entors Must					Informa	ation	blocks i	may b	Add		
Corre	sponden	ce In	formati	on:								
	either Custor rther informa					espon	denc	e Inform	nation	section below.		
An Address is being provided for the correspondence Information of this application.												
Customer Number 00832												
Email Address jfhoffma@bake					d.com Add Email Remove Email					Email		
Application Information:												
Title of the Invention GALACTOMANNANS AND/OR GLUCOMANNANS FOR INCREASING THE BIOAVAILABILITY OF ACTIVE SUBSTANCES												
Attorney Docket Number RBL0109-01							Sı	mall Ent	ity Sta	tus Claimed 🔀		
Application Type Nonprovisional				onal					-		-	
Subject Matter Utility												
Sugge	sted Class (i	if any)					S	ub Class	s (if an	y)		
Sugge	Suggested Technology Center (if any)											
Total Number of Drawing Sheets (if any)				3		S	uggeste	d Figu	re for Publication (if any)			

PTO/SB/14 (08-05)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data C	25 0 C D 4 7 C	Attorney D	orney Docket Number RBL0109-0					
Application Data S	Application	n Number						
Title of Invention GALACTOMANNANS AND/OR GLUCOMANNANS FOR INCREASING THE BIOAVAILABILITY OF ACSUBSTANCES								
Publication Information:								
Request Early Publication (Fee required at time of Request 37 CFR 1.219) Request Not to Publish. I hereby request that the attached application not be published under 35 U.S.C. 122(b)								
and certify that the invention disclosed in the attached application has not been and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing.								
Representative I	nformation:					•		
Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32). Enter either Customer Number or complete the Representative Name section below. If both sections are completed the Customer Number will be used for the Representative Information during processing.								
Please Select One:	Please Select One: Customer Number US Patent Practitioner US Representative (37 CFR 11.9)							
Customer Number	00832	•		· · · · · · · · · · · · · · · · · · ·				
Domestic Priority Information: This section allows for the applicant to claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c). Providing this information in the application data sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78(a)(2) or CFR 1.78(a)								
(4), and need not otherwis Prior Application Stat		Cilication.			Re	move	·	
Application Number	Type				ate (YYYY-MM-DD)			
Application Number	Continuity	Туре	10780152	on number	2004-02-17		-101101-00	
Drian Application Stat			Remove					
Prior Application Stat			Daina Anniin at		2Mar: Fficero	es desegna des desegna actual de la companya de la		
Application Number Continuity			Prior Application Number		Filing Date (YYYY-MM-DD)			
a 371 of international PCT/EP05/01546 2005-02-16								
Additional Domestic Priority Data may be generated within this form by selecting the Add button.								
Foreign Priority Information:								
This section allows for the applicant to claim benefit of foreign priority and to identify any prior foreign application for which priority is not claimed. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55(a).								
					Re	move		
Application Number	y i	Parent Filing Date (YYYY-MM-DD)			Priorit	y Claimed		
10 2004 008 017.8	DE		2004-03-17				○ No	
Additional Foreign Priority Data may be generated within this form by selecting the Add button.								

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Da	ata Sheet 37 CFR 1.76	Attorney Docket Number	RBL0109-01		
Application be	ita Sheet 57 Of K 1.70	Application Number			
Title of Invention	GALACTOMANNANS AND/O SUBSTANCES	R GLUCOMANNANS FOR INC	REASING THE BIOAVAILABILITY OF ACTIVE		

Assignee Information:

	<u>.</u>			
	n in the application data shee ssignment recorded in the Off		ubstitute for compliance w	vith any requirement of part 3 of Title 37
Assignee 1				
If the Assignee is an O	organization check here.	X		
Organization Name	Wheli Inter AG			
Mailing Address Info	rmation:			
Address 1	Gartenstrasse 2	E		
Address 2				
City	Zug		State/Province	
Country CH			Postal Code	CH-6300
Phone Number			Fax Number	
Email Address				_
Additional Assignee Dibutton.	ata may be generated wi	thin this for	rm by selecting the Ad	ld

Signature:

A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 10.18. Please see 37 CFR 1.4(d) for the form of the signature.								
Signature	/John F. Hoffman/		Date (YYYY-MM-DD)	2006-05-04				
First Name	John F.	Last Name	Hoffman	Registration Number	26,280			

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an
 individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of
 the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.